Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 493-497

  Chung, Jun Won ^a   Lee, Gin Hyug ^b   Jeong, Jin Yong ^b   Lee, Sun Mi ^b   Jung, Ji Hoon ^b   Choi, Kee Don ^b   Song, Ho June ^b   Jung, Hwoon Yong ^b   Kim, Jin Ho ^b  

^a Gachon University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Antibiotics resistance; Fluoroquinolone; Helicobacter pylori; Mutation

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; GENE MUTATION; HELICOBACTER PYLORI; KOREA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 84863149221     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06874.x     Document Type: Article

References (36)

1. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-9.
2. Malfertheiner P, Megraud F, O'Morain C etal. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007; 56: 772-81.
3. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007; 102: 1808-25.
4. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J. Gastroenterol. 2009; 54: 269-78.
5. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007; 12 (Suppl. 2): 50-8.
6. Chung JW, Lee GH, Han JH etal. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011; 58: 246-50.
7. Kim BG, Lee DH, Ye BD etal. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-5.
8. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther. 2004; 20: 99-107.
9. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect. Dis. 2006; 6: 699-709.
10. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-600.
11. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 1997; 40: 639-51.
12. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J. Gastroenterol. 2008; 14: 5385-402.
13. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. 2006; 101: 488-96.
14. Rokkas T, Sechopoulos P, Robotis J, Pistiolas D. Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. Am. J. Gastroenterol. 2006; 101: 1938. author reply -9.
15. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 2003; 47: 3942-4.
16. Miyachi H, Miki I, Aoyama N etal. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006; 11: 243-9.
17. Performance standards for antimicrobial susceptibility testing; 15th informational supplement M100-S15. Wayne, clinical and laboratory standards institute, 2005. In: institute CaLS, NCCLS): Cf, eds. 2005.
18. Bang SY, Han DS, Eun CS etal. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease. Korean J. Gastroenterol. 2007; 50: 356-62.
19. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J. Gastroenterol. 2006; 47: 337-49.
20. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J. Antimicrob. Chemother. 2005; 56: 965-7.
21. Nishizawa T, Suzuki H, Kurabayashi K etal. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob. Agents Chemother. 2006; 50: 1538-40.
22. Nishizawa T, Suzuki H, Hibi T. Quinolone-based third-line therapy for Helicobacter pylori eradication. J. Clin. Biochem. Nutr. 2009; 44: 119-24.
23. Lee CC, Lee VW, Chan FK, Ling TK. Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008; 54: 50-3.
24. Zullo A, Perna F, Hassan C etal. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment. Pharmacol. Ther. 2007; 25: 1429-34.
25. Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW. Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J. Clin. Microbiol. 2004; 42: 4832-4.
26. Zou J, Yang ZX, Qin ZM. Laboratory and clinical study of levofloxacin against Helicobacter pylori. Zhonghua Yi Xue Za Zhi 2003; 83: 1778-81.
27. Cheon JH, Kim N, Lee DH etal. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006; 11: 46-51.
28. Lee JH, Hong SP, Kwon CI etal. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J. Gastroenterol. 2006; 48: 19-24.
29. Yoon H, Kim N, Lee BH etal. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009; 14: 77-85.
30. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob. Agents Chemother. 2009; 53: 1720-1.
31. Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 2008; 23 (Suppl. 2): S167-70.
32. Matsuzaki J, Suzuki H, Tsugawa H, Nishizawa T, Hibi T. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target ofquinolone-based eradication therapy. J. Gastroenterol. Hepatol. 2010; 25 (Suppl. 1): S7-10.
33. Nishizawa T, Suzuki H, Umezawa A etal. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J. Clin. Microbiol. 2007; 45: 303-5.
34. Kim N, Kim JM, Kim CH etal. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J. Clin. Gastroenterol. 2006; 40: 683-7.
35. Sung H, Chung HJ, Kim MN, Lee GH. Clinical usefulness of antimicrobial susceptibility test for Helicobacter pylori. Korean J. Lab. Med. 2006; 26: 179-84.
36. Lee BH, Kim N, Hwang TJ etal. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010; 15: 38-45.